David Witter

David Witter

Company: Cullinan Oncology

Job title: VP, Preclinical Research


Enhancing Tyrosine Kinase Inhibitor Success in NSCLC Through Maximizing Potent Activity Against Exon20 Insertion (Ex20ins) Mutations with a Novel, Oral EGFR Inhibitor 4:00 pm

Developing an EGFR inhibitor which targets Ex20ins mutations with high potency while sparing the WT EGFR activity Overcoming toxicities related to inhibition of wild-type EGFR, including rash and diarrhea, which can compromise the use of EGFR Ins20 inhibitors Presenting the latest clinical data from Cullinan’s phase 2a study with the selective candidate, CLN-081Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.